Electrochemical Properties of Fused Pyrimidine-Triazole Heterocyclic Molecules as Novel Drug Candidates

Short title: Electrochemical Properties of Pyrimidine-Triazole Heterocyclic Molecules

Fatma Kurul1, Hüseyin Istanbullu2, Hüseyin Öğüzhan Kaya3, Arif E. Çetin4, Seda Nur Topkaya1
1Izmir International Biomedicine and Genome Institute, Dokuz Eylül University
2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University
3Department of Analytical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University
4Izmir Biomedicine and Genome Center, Balcova, Izmir 35340, Turkey

Corresponding Author Information
Seda Nur Topkaya
sedanur6@gmail.com
14.02.2023
13.05.2023
16.05.2023

ABSTRACT

INTRODUCTION: Triazolopyrimidinones are a type of compound used in medicinal chemistry. In this study, three novel triazolopyrimidinone derivatives were synthesized as drug candidates which are named ((5-(Chloromethyl)-2-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one) (S1-TP), 2-(4-Methoxyphenyl)-5-(piperidinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one (S2-TP), and 2-(4-Methoxyphenyl)-5-(morpholinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one (S3-TP). Their electrochemical properties were investigated for the first time with voltammetric techniques on carbon graphite electrodes. Moreover, stability tests for each drug candidate were performed on different days. After revealing the electrochemical properties of drug candidates, their effect on double-stranded (ds) DNA was examined by measuring the oxidation currents of the guanine of dsDNA before and after the interaction.

METHODS: An electrochemical setup that included a pencil graphite electrode as the working electrode, an Ag/AgCl reference electrode, and a platinum wire as the auxiliary electrode was used in this study. The experiments for optimum pH, scan rate, and concentration of drug candidates were conducted. The interaction between Ss-TP and dsDNA was evaluated using differential pulse voltammetry. The stability of each drug candidate was tested on various days.

RESULTS: A comprehensive characterization of the S1-TP, S2-TP and S3-TP compounds was studied for the first time. This study showed that the electrochemical oxidation of S1-TP and S2-TP was irreversible and diffusion-controlled. Additionally, the transfer of electrons in S3-TP was controlled by adsorption. The interaction between Ss-TP and dsDNA resulted in notable changes in the dsDNA peak potential. The dsDNA peak potential shifted negatively after interaction with S1-TP, S2-TP, and S3-TP. Under optimum conditions, the detection limits for S1-TP, S2-TP, and S3-TP were 1.5 µg/mL, 1.0 µg/mL, and 2.0 µg/mL, respectively.

DISCUSSION AND CONCLUSION: From our experimental data, we concluded that these molecules can be used as drug molecules for their remarkable effects on DNA.

Keywords: Drug Candidate, Drug, DNA, Drug-DNA Interaction, Triazolopyrimidinone, Heterocyclic compounds.
1. INTRODUCTION
Triazolopyrimidinones, a class of fused pyrimidinone-triazole heterocyclic ring systems, are considered privileged scaffolds in medicinal chemistry. A wide range of bioactivity of the triazolopyrimidinone bearing compounds has been reported as FABPs, ferrochelatase, and PAS Kinase inhibitors (1,2). Additionally, triazolopyrimidinones and triazolopyrimidines with purine bioisosteric analogues are reported to have anticancer activity through various mechanisms (3). Fandzloch et al. reported that triazolopyrimidine ruthenium(II) complexes show anticancer activity on various cancer cell lines, and these complexes bind to the minor groove of DNA or intercalate it (4). In another study, triazolopyrimidine copper(II) complexes and their DNA intercalating capacity were analyzed with absorption and fluorescence spectrums (5). The results suggested that the complexes were intercalated into DNA strands as well as their damage through metalonuclease activity. Harrison et al. discovered a selective and highly soluble triazolopyrimidine derivative molecule as an NLRP3 inflammasome inhibitor using in silico pharmacophore model, which could be used as an inhibitor for the treatment of inflammatory diseases (6).

Drug and drug candidates can interact with DNA in several ways, and the interaction between them can be determined with various instrumental methods such as circular dichroism (CD), nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FTIR), viscosity measurements, infrared spectroscopy (IR), mass spectrometry (MS), molecular docking, and electrochemical methods (7–15). Morawska et al. developed a voltammetric method to observe the electrochemical behavior of tenofovir and its interaction mechanism with ds/ssDNA, and compared their method with spectrophotometric analyses, where the electrochemical method showed better analytical performance compared to spectrophotometry in terms of LOD and linear range (11). In another study, the interaction mechanism of mitoxantrone and DNA molecule was studied employing FTIR, UV–Vis, and CD. According to spectrophotometric results, mitoxantrone possibly binds to DNA from guanine (N7), thymine (O2) and cytosine (O2) locations (16). Electrochemical methods are preferred due to their rapidness, high selectivity, low instrumentation cost, simple operation, and portability. They could reveal the chemical properties and potential toxic effects of drug candidates and determine the metabolic processes (17).

The main interaction modes between the drug molecules and DNA can be simply classified as covalent and non-covalent binding. Among them, covalent binding with DNA is irreversible, inhibits the functions of DNA, and leads to cell death. Contrarily, non-covalent binding is reversible, and they are sub-classified as electrostatic, groove, and intercalative bindings. Electrostatic binding results from the interactions of positively charged ligands with the negatively charged DNA phosphate backbone structure. Groove binding is also sub-categorized as minor and major groove binding which small ligands bind to the minor or major groove of DNA by van der Waals or hydrogen bonds. Small ligands could bind to DNA via unique binding sites and this mode is called as intercalation. In this mode, Intercalators containing planar heterocycle groups could slide and stack between base pairs of DNA and stabilize the duplex without breaking the base pair or forming covalent bonds. Our study is the first report analyzing the electrochemical properties of novel triazolopyrimidinimone derivatives as purine analog chemical structures. First, we investigated the electrochemical properties of novel drug candidates, and then their interaction with dsDNA was analyzed with voltammetric methods as Differential Pulse Voltammetry (DPV) and Cyclic Voltammetry (CV). Experimental parameters, e.g., pH, concentration of drug candidates, and scan rate were examined for revealing the analytical properties of these novel drug candidates. Stability tests were performed with optimal storage conditions and within different days to observe the shelf life of the drug candidates.

2. MATERIALS AND METHODS

2.1 Materials
The salmon sperm DNA used in this experiment (Sigma Aldrich, purity ≥ 98%) was dissolved in deionized water to prepare stock solutions. 3-amino-5-(methylthio)-4H-1,2,4-triazole (Merck, purity ≥ 97%) and chloroform (Alfa Aesar-Acros Organics, purity ≥ 99%) were used as received without further purification. The buffers were prepared using analytical grade chemicals from various companies as Carlo Erba, Alfa Thermo Fisher Scientific, and Isolab. In the experiments, we used 0.5 M Acetate (ACB, pH: 3.8, 4.8, 5.6) and 0.05 M Phosphate (PBS, pH: 7.4) buffers involving 0.02 M NaCl and 0.05 M Tris-EDTA (TE, pH: 8.0) buffer.

2.2 Instrumentation
Analytical thin layer chromatography (TLC) was used with Merck silica gel F-254 plates. Melting points were employed with Stuart SMP 30 (Staffordshire, ST15 OSA). NMR spectra were reported with Varian AS 400 Mercury plus NMR (Varian Inc.) spectrometer at 400 MHz for 1H and 100 MHz for 13C using DMSO-d6 as solvent. The coupling constants (J) were presented in Hertz (Hz) without internal standard. Splitting patterns were designated as follows: s (singlet); d (doublet); t (triplet); p (pentet) and m (multiplet). HR-MS were determined on Agilent 6200 Series TOF and 6500 Series Q-TOF LC/MS System with ESI (+) ionization. Microwave irradiation (MW) synthesis of...
the compounds was conducted on Milestone MicroSYNTH (Milestone S.r.l.) microwave apparatus. PalmSens4 handheld analyzer with PSTrace 5.8 software were used for electrochemical studies. Pencil graphite electrodes were employed as working electrodes. To complete the three-electrode system, a platinum wire and an Ag/AgCl electrode were employed as auxiliary and reference electrodes, respectively.

2.3 Experimental

2.3.1 General Synthesis of Drug Candidates

The synthesis steps are shown in Figure 1.

**Synthesis of substituted triazole**

5-(4-metoxyphenyl)-3-amino-1,2,4-triazole was synthesized according to reference (18). In the first step, aminoguanidine bicarbonate and 4-metoxybenzoyl chloride were reacted. Later, the amide derivative underwent cyclization to yield 5-(4-metoxyphenyl)-3-aminotriazole.

**Synthesis of S1-TP**

5-(4-metoxyphenyl)-3-amino-1,2,4-triazole (10 mmol) and ethyl 4-chloroacetoacetate (20 mmol) were mixed in 18 mL acetic acid (MW, 20 min, 180°C). The formed solid was filtered off, rinsed with acetic acid, and dried. These steps resulted to yield S1-TP (5-(Chloromethyl)-2-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one, which was used in the next steps without purification.

**Synthesis of S2-TP and S3-TP**

In the last step of the synthesis, the nucleophilic substitution of the obtained S1-TP with piperidine and morpholine yield S2-TP and S3-TP. S1-TP (1 mmol) and amine derivatives namely, piperidine/morpholine (2 mmol) were stirred in 16 mL DMF in the presence of 1.5 mmol caesium carbonate (Cs₂CO₃) using MW irradiation (150 W, 15-30 min, 95°C). The excess of Cs₂CO₃ was filtered, and the filtrate was concentrated under reduced pressure. This mixture was further purified by column chromatography over silica gel 60 (70-230 mesh ASTM, Merck) with chloroform/methanol (10:2) and the compounds were recrystallized from methanol or acetone. The crude yield is 40-45%.

**S2-TP:** 2-(4-Methoxyphenyl)-5-(piperidinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one

**S3-TP:** 2-(4-Methoxyphenyl)-5-(morpholinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one

![Figure 1](image1.png)

**Figure 1.** General synthesis scheme of the pyrimidine-triazole derivatives: S1-TP, S2-TP, and S3-TP. The characterization results are presented in supplementary information.

2.3.2 Electrochemical Investigation of the Drug Candidates
+1.4 V potential for 30 s was applied to activate and clean the PGEs. 1000 µg/mL of dsDNA was prepared with TE buffer and diluted with ACB. 1000 µg/mL of drug candidates were prepared in dimethylformamide (DMF) and diluted to with proper buffers. These solutions were then added to the electrochemical measuring cell. Activated PGEs were dipped in these solutions, and DPV measurements were performed.

2.3.3 Interaction
Solutions containing 50 µg/mL of dsDNA and 10 µg/mL of drug candidates were mixed in ACB (pH: 3.8 for $S_1$-TP/DNA, $S_2$-TP/DNA; and pH: 5.6 for $S_3$-TP/DNA). The solutions were then placed in the thermal shaker at 600 rpm and 45°C for 30 min. Then, 100 µL of this interaction solution was put into the tubes. The PGEs were dipped in the interaction solutions for 30 min. Then, DPV measurements were performed.

2.3.4 Measurement
DPV and CV measurements were performed from +0.4 and +1.4 V at 100 mV/s scan rate with 0.5 s interval time. The experimental steps are illustrated in Figure 2.

3. RESULTS AND DISCUSSION
3.1. Synthesis of Compounds
Three novel drug candidates were synthesized as below:

5-(Chloromethyl)-2-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one ($S_1$-TP).
Yellow solid; yield, 52 %; m.p., 113 °C; 1H-NMR (DMSO-d$_6$, 400 MHz) δ 8.02 (d, J = 8.7 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 6.16 (s, 1H), 4.66 (s, 2H), 3.81 (s, 3H) ppm; 13C-NMR (DMSO-d$_6$, 100 MHz) δ 161.6, 156.1, 151.8, 128.7, 114.8, 100.4, 55.8 ppm; C13H11ClN4O2 HRMS m/z: 290.0552 (Calcd for 290.05705)

2-(4-Methoxyphenyl)-5-(piperidinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one (S$_2$-TP)

Yellow solid; yield, 30 %; m.p., 128 °C; 1H-NMR (DMSO-d$_6$, 400 MHz) δ 8.01 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 5.63 (s, 1H), 3.79 (s, 3H), 3.30 (s, 2H), 2.34-2.42 (m, 2H), 1.50 (p, J = 5.5 Hz, 4H), 1.34-1.43 (m, 2H) ppm; 13C-NMR (DMSO-d$_6$, 100 MHz) δ 162.39, 160.28, 159.72, 158.74, 128.12, 125.96, 114.21, 94.35, 65.34, 55.59, 54.70, 26.19, 24.47 ppm; C18H21N5O2 HRMS m/z: 339.16979 (Calcd for 339.16952).

2-(4-Methoxyphenyl)-5-(morpholinomethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(3H)-one (S$_3$-TP)

Yellow solid; yield, 35 %; m.p., 103 °C; 1H-NMR (DMSO-d$_6$, 400 MHz) δ 8.02 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 5.66 (s, 1H), 3.79 (s, 3H), 3.53-3.65 (m, 4H), 3.28 (s, 2H), 2.37-2.47 (m, 4H) ppm; 13C-NMR (DMSO-d$_6$, 100 MHz) δ 161.27, 160.51, 160.34, 159.55, 158.65, 128.16, 125.82, 114.23, 94.76, 66.76, 64.72, 55.59, 53.91 ppm; C17H19N5O3 HRMS m/z: 341.14814 (Calcd for 341.14879).

The designed compounds were synthesized in three steps (Figure 1). The structures of the final compounds were determined by spectral analyses and the spectroscopic data confirmed the proposed structures. In the 1H NMR spectra, hydrogen atom of the heterocyclic ring was observed as a singlet signal between δ 5.63–6.16 ppm. The methylene protons, attached to heterocyclic ring at 5 positions, were observed as singlet with two proton integrals between δ 4.66 – 3.28 ppm. Proton signals of the benzene ring and cyclic amines were identified in the expected chemical shifts with expected divisions. The observed carbon signals in the 13C NMR of the compounds were in accordance with the target compounds. The amide carbon signal was observed between δ 161–162 ppm in 13C NMR spectrums.

The purity of the compounds was determined with HRMS spectra. The HRMS data were in accordance with the molecular formula and a found value within 0.003 m/z unit of the calculated value of a parent-derived ion. S$_2$-TP and S$_3$-TP were introduced earlier in the literature (19), while the full spectral characterization of these compounds was for the first time introduced in this article.

3.2 Electrochemical Properties of Drug Candidates

In this part, the electrochemical behaviors of the drug candidates were analyzed with DPV. As pH is quite important for the metabolism of drug molecules, the effect of pH on the oxidation signals of drug candidates was examined and the obtained results were shown in Figure 3.

![Figure 3](https://example.com/figure3)

**Figure 3.** (A) Effect of pH on peak currents. Bar graphs: drug candidates in different pH values, 3.8 to 7.4. (B) DPV voltammogram of S$_1$-TP, S$_2$-TP, and S$_3$-TP prepared in ACB (pH: 3.8 for S$_1$-TP and S$_2$-TP, and pH: 5.6 for S$_3$-TP).
For the pH study in DPV, drug candidates were prepared using buffers with pH ranges from 3.8 to 7.4. As shown in Figure 3A, S₁-TP and S₂-TP produced stable responses, and the highest currents were obtained at pH 3.8. S₁-TP showed the highest electrochemical signals at pH 5.6. Thus, pH 5.6 was chosen for the dilution buffer for S₃-TP (Figure 3A).

At pH 3.8, the oxidation peak potentials of S₁-TP were detected at 1.03 V and 1.15 V. As it is more stable and higher, the signal obtained at 1.03 V was chosen as the main oxidation signal for further studies. At pH 3.8, S₂-TP gave two oxidation signals at 0.79 V and 1.11 V. At pH 5.6, the oxidation peak potentials of S₃-TP were observed at 0.76 V and 1.04 V (Figure 3B). All oxidation signals were shifted to lower potentials with pH. These shifts in peak potentials for drugs demonstrate that protons participate in the oxidation process of drugs (20).

As shown in Figure 3B, all drug candidates have oxidation capacity. Triazolopyrimidinone structure could form triazolopyrimidinol by an H atom shifting, tautomerization. Several factors could contribute to the stability between two tautomers, e.g., substitution, aromaticity, hydrogen bonding, and solvation. The redox mechanism of these novel agents on graphite electrode surfaces could involve the oxidation of phenol groups of the compounds. Heteroatoms in the substituted amines might also contribute to the oxidation potency of the compounds, e.g., they could change the oxidation potency. Considering the phenolic tautomerization of the heteroaromatic ring and the amine substitution, the title compound could possess oxidative properties.

In the second part of our study, DPV measurements were performed at different concentrations of drug candidates at 100 mV/s to determine the analytical concentration ranges for the drug candidates (Figure 4).

The formulas for calculating Limit of detection (LOD) and limit of quantification (LOQ) depend on the specific method used, but generally, LOD is calculated as 3 times the standard deviation of the response (ss) divided by the slope of the calibration curve (m), while LOQ is calculated as 10 times the standard deviation of the response divided by the slope of the calibration curve

\[
\text{LOD} = \frac{3s}{m}
\]

\[
\text{LOQ} = \frac{10s}{m}
\]

LOD and LOQ were determined from Figure 4. For S₁-TP and S₂-TP, LOD and LOQ were calculated from the concentrations 5, 10, 15, and 20 μg/mL. For S₃-TP, LOD and LOQ were calculated from the concentrations 2.5, 5, 10, and 20 μg/mL. LOD and LOQ for S₁-TP are 1.5 μg/mL and 5.0 μg/mL, respectively (Figure 4A). LOD and LOQ for S₂-TP are 1.0 μg/mL and 3.4 μg/mL, respectively (Figure 4B). LOD and LOQ for S₃-TP are 2.0 μg/mL and 6.8 μg/mL, respectively (Figure 4C). The correlation coefficients are 0.9990, 0.9988, and 0.9930 for S₁-TP, S₂-TP, and S₃-TP, respectively.

The effects of scan rate (V) on peak current (Iₚ) were studied using CV between 25-150 mV/s as shown in Figure 5.
Figure 5: Effect of (A) scan rate and (B) scan rate root on peak current, and (C) scan rate on the log of peak current.

As shown in Figure 5A, the anodic peak current ($I_{pa}$) has a linear relationship with scan rate ($\nu$):

$$S_1\text{-TP}: I_{pa} (\mu A) = 0.374\nu + 17.666 \quad (R^2=0.9990) \quad (Equation~1)$$

$$S_2\text{-TP}: I_{pa} (\mu A) = 0.1316\nu + 6.2628 \quad (R^2=0.9880) \quad (Equation~2)$$

$$S_3\text{-TP}: I_{pa} (\mu A) = 0.2254\nu + 2.2687 \quad (R^2=0.9980) \quad (Equation~3)$$

As shown in Figure 5B, peak current ($I_{pa}$) also has a linear relationship with the root of the scan rate ($\nu^{1/2}$):

$$S_1\text{-TP}: I_{pa} (\mu A) = 203.97\nu^{1/2} - 7.7443 \quad (R^2=0.9928) \quad (Equation~4)$$

$$S_2\text{-TP}: I_{pa} (\mu A) = 72.771\nu^{1/2} - 2.9923 \quad (R^2=0.9977) \quad (Equation~5)$$

$$S_3\text{-TP}: I_{pa} (\mu A) = 122.95\nu^{1/2} - 13.05 \quad (R^2=0.9920) \quad (Equation~6)$$

In Figure 5C, $\log(I_{pa})$ and $\log(\nu)$ linear relationship was presented within the scan rate range between 25 mV/s and 150 mV/s:

$$S_1\text{-TP}: \log I_{pa} = 0.5716\log \nu + 2.3213 \quad (R^2=0.9937) \quad (Equation~7)$$

$$S_2\text{-TP}: \log I_{pa} = 0.5996\log \nu + 1.899 \quad (R^2=0.9987) \quad (Equation~8)$$

$$S_3\text{-TP}: \log I_{pa} = 0.8568\log \nu + 2.2551 \quad (R^2=0.9978) \quad (Equation~9)$$

According to the literature, these slope values are close to the theoretical value, e.g., 0.5, indicating the diffusion-controlled processes, while for the theoretical value 1, the process is adsorption-controlled (21). Slopes of Equation 7 and Equation 8 were determined as 0.5716 and 0.5996, respectively, which indicates that electrochemical oxidations of $S_1$-TP and $S_2$-TP are diffusion-controlled processes. According to Equation 9, the slope is 0.8568, which proves that the electrode process was adsorption controlled for $S_3$-TP.

3.3 INTERACTION

The intrinsic electro-activity of adenine and guanine bases are generally used as an indicator for drug-DNA interactions. In the next step of our study, we studied the interaction of drug candidates with dsDNA. 100 µg/mL dsDNA solutions were prepared with TE buffer (pH: 8.0).

The stock drug solutions were prepared with DMF and diluted with ACB (pH: 3.8 for $S_1$-TP and $S_2$-TP, and pH: 5.6 for $S_3$-TP). The final concentrations of dsDNA and Ss-TP were 50 µg/mL and 10 µg/mL, respectively. All solutions were placed in the thermal shaker, where stirring was applied at 600 rpm and 45 °C for 30 min. Then, 100 µL of the solution was transferred into tubes, and the electrodes were immersed in these tubes for 30 min. Oxidation signals were measured with DPV in the range between 0 and 1.4 V at 50 mV/s scan rate in the absence and the presence of drug candidate molecules. The analytical signals associated with the guanine bases of DNA were obtained at ∼1.0 V vs. Ag/AgCl.
Figure 6. Differential pulse voltammograms of guanine oxidation currents of dsDNA after interaction with (A) S₁-TP, (B) S₂-TP, and (C) S₃-TP. Experimental steps are: PGE pretreatment: 1.4 V for 30 s, Interaction: 100 μg/mL of dsDNA and 20 μg/mL of drug candidates, Stirring: 600 rpm at 45 °C for 30 min, Adsorption: 30 min, and DPV measurement within a range between 0 and +1.4 V at 50 mV/s in ACB.

In Figure 6A, two distinct oxidation signals associated with dsDNA in ACB (pH: 3.8) were obtained at +0.92 V and +1.17 V, respectively. After the interaction with S₁-TP, the peak potential of dsDNA shifted to +0.89 V and +1.16 V, respectively. On the other hand, after the interaction with S₂-TP, one of the peak potentials of dsDNA shifted negatively from +0.92 V to +0.89 V. Oxidation signals of dsDNA in ACB (pH: 5.6) were obtained at +0.92 V and +1.18 V. In the presence of S₃-TP, the peak potentials of dsDNA slightly shifted toward smaller values, e.g., +0.90 V and +1.16 V. In Figure 6C, dsDNA oxidation potentials shifted negatively after interacting with S₁-TP, S₂-TP, and S₃-TP. Here, positive or negative shifts on peak potential can reveal the interaction mechanism between the drug candidate and dsDNA. Positive peak potential shifts are associated with intercalative binding, while negative peak potential shifts are associated with electrostatic binding (22). Bilge et al. reported the interaction mechanism between ibrutinib (IBR) and dsDNA using electrochemical and molecular docking techniques. Voltametric studies indicated that the peak potential of IBR shifting towards less positive potentials as a result of electrostatic interaction (23). In our study, the shift in the peak potential towards the negative could be attributed to the irreversible electrode process (24). The reason for this shift could be explained by electrostatic binding between Ss-TP and dsDNA.

In Figure 6A, the peak currents of dsDNA were found as 3.95 μA and 4.79 μA with the relative standard deviation (RSD) 5.45%, 3.76% which decreased to 1.30 μA and 3.11 μA after the interaction with RSD 3.12%, 4.87% (n=5). In Figure 6B, the peak currents of dsDNA were found as 4.94 μA and 4.86 μA with RSD 1.68%, 4.54% which increased, e.g., 6.92 μA with RSD 3.95%, 7.62% and 8.08 μA with RSD 4.97%, 5.23%, due to the binding of S₂-TP to dsDNA, changing the dsDNA structure. Figure 6C demonstrates that S₃-TP caused a significant change in the oxidation currents of dsDNA. Here, the peak currents of dsDNA are as 5.42 μA with RSD 2.97%, and 5.58 μA with RSD 7.66% while after interaction we determined three peaks at 3.07 μA with RSD 5.22%, 1.66 μA with RSD 9.13%, and 5.03 μA with RSD 4.68%.

3.4 STABILITY

Stability is one of the most important factors that are related to the efficacy of drug candidates. To evaluate the stability of the drug candidates, we performed DPV (Figure 7). The stock solutions of drug candidates were freshly prepared and stored in dark at room temperature (25 °C). Stock solutions of drug candidates measured within 0, 5, 7, 14, and 30 days. Here, S₁-TP and S₃-TP exhibited good stability for 30 days of storage without significant percentage changes in current values, e.g., we observed a slight reduction in the percentage of current for S₁-TP between day 0 and 30. At the end of day 30, the percentage of the current value for S₁-TP was determined as 91%. A noticeable change in the percentage current of S₂-TP was observed at day 30, e.g., 48%. In contrast, minute changes in current values of S₂-TP were observed between day 7 and 30, e.g., the current value of S₂-TP decreased to 86% at day 30. These results proved that the stock solutions of drugs were stable for 30 days, except S₂-TP, which could be very advantageous for long-term use by retaining their pharmaceutical properties.
Figure 7. Change in current for S₁-TP, S₂-TP, and S₃-TP examined at 25 °C for different days, e.g., 0, 5, 7, 14, and 30. Percentage current values of drug candidates were 91%, 48%, and 86% by the end of 30 days, respectively.

4. CONCLUSION

In conclusion, in this article, we for the first time studied the full characterization of S₁-TP, S₂-TP, and S₃-TP compounds. Importantly, S₁-TP is reported for the first time in the literature, while S₂-TP and S₃-TP compounds were reported in the literature for only their screening activity against FABPs (Patent No; WO 2010/056630 A1). We introduced the synthetic pathway and full spectral characterization data of these compounds to the literature. Our article focused on the electrochemical behaviors of S₃-TP and their interactions with dsDNA using DPV and CV. We showed the interaction of S₃-TP–dsDNA resulted in significant changes on dsDNA peak potential. dsDNA peak potential shifted negatively after the interaction with S₁-TP, S₂-TP, and S₃-TP. The shift of dsDNA peak potential reveals the interaction of S₃-TP with DNA supporting the binding in between. Moreover, the shift in the peak potential of dsDNA towards more positive values indicates that DNA-drug interaction mechanism is intercalation, while the shift towards more negative value indicates that DNA-drug interaction mechanism is an electrostatic mode. Our study also showed that electrochemical oxidation processes of S₁-TP and S₃-TP were irreversible and controlled by diffusion. In addition, the electron transfer process was an adsorption-controlled process for S₁-TP. We believe our study can provide critical information for understanding the DNA-drug interaction that could be very advantageous to analyze new drug compounds and their potential effect on target biomolecules.

REFERENCES

auxiliary n-n-chelating heterocycle ligands. Molecules. 2021;26(22).
Figure 1. $^1$H NMR Spectra of S$_2$TP.
Figure 2. $^{13}$C NMR Spectra of Si-TP.
Data Sheet. HRMS data of S1-TP
Figure 3. $^1$H NMR Spectra of S$_2$TP
Figure 4. $^{13}$C NMR Spectra of S$_2$-TP
Data Sheet. HRMS data of S2-TP
Figure 5. $^1$H NMR Spectra of $S_3$TP
Figure 6. $^{13}$C NMR Spectra of S$_3$TP.
Data Sheet. HRMS data of S$_3$-TP